Phase 2 N=6 Apremilast for Erythema Multiforme
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift
Temporary Auditory Threshold Shift
Primary: Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population — 3.23; 1.32; 3.81; 4.07 dbHL — p=<0.05
Phase 2 N=20 Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
Cytokine Release Syndrome · ICANS · Lymphoma, Non-Hodgkin
Primary: Participants With a Complete Response for Cytokine Release Syndrome (CRS) — 15 Participants
Phase 2 N=59 Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
Chronic Kidney Disease
Primary: Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 — -1.755; -9.253 mmHg
Phase 2 N=5 A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
Plague
Primary: Number of Participants Achieving Clinical Cure — 5 Participants
Phase 2 N=27 A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Progressive Familial Intrahepatic Cholestasis · Alagille Syndrome · Cholestatic Liver Disease
Primary: Frequency of Treatment-emergent Adverse Events [TEAEs] — 16; 10; 4; 3 Participants
Phase 2 N=158 A Study of TAK-341 in Treatment of Multiple System Atrophy
Multiple System Atrophy
Primary: Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52 — 5.58; 5.54 score on a scale — p==0.961
Phase 2 N=77 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Chronic GVHD — 17; 20; 14; 17 Participants
Phase 2 N=16 Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
Uveal Melanoma With Liver Metastases
Primary: Objective Response Rate (ORR) — 3 Participants
Phase 2 N=25 Unacylated Ghrelin to Improve Functioning in PAD
Peripheral Artery Disease
Primary: 4-month Change in Six-minute Walk Distance — -17.13; 23.06 meters — p=0.9640
Phase 2 N=35 Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Cancer · Head and Neck Cancer · Head and Neck Neoplasms
Primary: Objective Response Rate — 13 Participants
Phase 2 N=23 sEphB4-HSA in Treating Patients With Kaposi Sarcoma
Skin Kaposi Sarcoma
Primary: Proportion of Participants Experiencing Clinical Response — 56.5 percentage of participants
Phase 2 N=227 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved Greater Than or Equal to (>=) 75 Percent (%) Improvement From Baseline in Psoriasis Area Severity Index Score (PASI-75) at LTE…
Phase 2 N=124 Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Metabolic Dysfunction-Associated Steatotic Liver Disease · Non-alcoholic Fatty Liver Disease · Nonalcoholic Fatty Liver Disease
Primary: Mean Relative Reduction From Baseline in Liver Fat Content at Week 28 — 67.8; 54.4; 42.1 Percent Reduction
Phase 2 N=40 Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects
Obesity; Overweight
Primary: Food Consumption — 605.5; 404.3; 423.6 weight food eaten g